Jennison Associates Has Cut Jpmorgan Chase & Co (JPM) Stake; MOLECULAR PARTNERS AG ORDINARY SHARES S (MLLCF) Shorts Decreased By 4.01%

JPMorgan Chase & Co. (NYSE:JPM) Logo

Jennison Associates Llc decreased Jpmorgan Chase & Co (JPM) stake by 6.73% reported in 2018Q4 SEC filing. Jennison Associates Llc sold 996,983 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.08%. The Jennison Associates Llc holds 13.82 million shares with $1.35B value, down from 14.82M last quarter. Jpmorgan Chase & Co now has $348.98B valuation. The stock increased 1.15% or $1.21 during the last trading session, reaching $106.55. About 24.81M shares traded or 63.12% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has declined 8.15% since March 17, 2018 and is downtrending. It has underperformed by 12.52% the S&P500. Some Historical JPM News: 18/05/2018 – VIENNA INSURANCE GROUP VIGR.Vl : JP MORGAN RAISES TARGET PRICE TO 27.5 EUROS FROM 25.5 EUROS; 15/05/2018 – Presenting at JPMorgan Conference Tomorrow; 10/05/2018 – Western Digital Presenting at JPMorgan Conference May 15; 13/04/2018 – JPMORGAN ASSET MGMT IS WORKING W/ OFAC ON RUSAL HOLDING; 14/05/2018 – MDC Holdings Presenting at JPMorgan Conference Tomorrow; 26/04/2018 – BOSTON SCIENTIFIC CORP BSX.N : JP MORGAN RAISES TARGET PRICE TO $32 FROM $31; 30/05/2018 – JPMorgan Growth Advantage Adds Spotify, Buys More Facebook; 16/05/2018 – BHP BILLITON PLC BLT.L : JP MORGAN RAISES TARGET PRICE TO 1650P FROM1640P; 17/04/2018 – JPMORGAN STAKE IN NORWEGIAN DROPS TO 4.49% AFTER SHARE ISSUE; 13/04/2018 – JPMORGAN CFO LAKE SPEAKS ON CONFERENCE CALL WITH MEDIA

MOLECULAR PARTNERS AG ORDINARY SHARES S (OTCMKTS:MLLCF) had a decrease of 4.01% in short interest. MLLCF’s SI was 445,300 shares in March as released by FINRA. Its down 4.01% from 463,900 shares previously. It closed at $19.36 lastly. It is down 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

Since October 19, 2018, it had 2 insider buys, and 5 sales for $4.86 million activity. 5,831 shares were sold by BACON ASHLEY, worth $599,304 on Sunday, January 13. $125,281 worth of JPMorgan Chase & Co. (NYSE:JPM) shares were bought by HOBSON MELLODY L. Beer Lori A also sold $1.40 million worth of JPMorgan Chase & Co. (NYSE:JPM) shares. CROWN JAMES S bought 5,000 shares worth $518,950. Petno Douglas B sold $1.22 million worth of stock. Friedman Stacey sold 3,022 shares worth $317,310. Another trade for 18,679 shares valued at $1.96M was made by Scher Peter on Tuesday, January 29.

Investors sentiment increased to 1 in 2018 Q4. Its up 0.05, from 0.95 in 2018Q3. It is positive, as 71 investors sold JPM shares while 735 reduced holdings. 135 funds opened positions while 667 raised stakes. 2.33 billion shares or 0.45% more from 2.32 billion shares in 2018Q3 were reported. Paragon Capital Mngmt Ltd holds 0.26% in JPMorgan Chase & Co. (NYSE:JPM) or 5,584 shares. Glenmede Na has invested 0.73% in JPMorgan Chase & Co. (NYSE:JPM). Portland Counsel holds 4,273 shares. Wheatland Advsr reported 9,083 shares stake. 1.93M are held by Brave Warrior Advsr Ltd. Motco stated it has 101,695 shares. Willow Creek Wealth Incorporated holds 0.12% or 2,359 shares in its portfolio. Locust Wood Capital Advisers Llc invested in 474,344 shares. Drexel Morgan And Co holds 0.29% or 3,000 shares in its portfolio. Bartlett & Llc accumulated 0.39% or 93,886 shares. Cibc World Markets Corp reported 0.78% stake. Sigma Planning holds 0.52% or 73,601 shares. Goodwin Daniel L accumulated 26,550 shares or 1.36% of the stock. Advisory Rech invested in 385,188 shares or 0.8% of the stock. Com Of Virginia Va invested in 1.33% or 92,720 shares.

Among 7 analysts covering JPMorgan Chase (NYSE:JPM), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. JPMorgan Chase had 11 analyst reports since September 26, 2018 according to SRatingsIntel. On Tuesday, January 8 the stock rating was maintained by Morgan Stanley with “Overweight”. Credit Suisse maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Friday, December 7. Credit Suisse has “Outperform” rating and $128 target. Barclays Capital maintained JPMorgan Chase & Co. (NYSE:JPM) on Thursday, February 21 with “Buy” rating. The firm has “Market Perform” rating given on Thursday, February 28 by BMO Capital Markets. BMO Capital Markets maintained it with “Market Perform” rating and $123 target in Wednesday, January 16 report. Wells Fargo maintained the shares of JPM in report on Thursday, February 14 with “Outperform” rating. Morgan Stanley maintained it with “Buy” rating and $124 target in Wednesday, February 27 report. Citigroup maintained the stock with “Neutral” rating in Wednesday, September 26 report. Jefferies downgraded the stock to “Hold” rating in Tuesday, January 8 report.

More notable recent JPMorgan Chase & Co. (NYSE:JPM) news were published by: which released: “Why Warren Buffett Thinks JPMorgan’s Stock Could Soar – The Motley Fool” on March 15, 2019, also with their article: “3 Reasons JP Morgan Is a Solid Blue-Chip Play –” published on March 15, 2019, published: “JPMorgan Goes Low In Search Of ETF Growth (NYSE:JPM) – Benzinga” on March 14, 2019. More interesting news about JPMorgan Chase & Co. (NYSE:JPM) were released by: and their article: “JPMorgan Chase to open first retail branches in Charlotte this year – Charlotte Business Journal” published on March 13, 2019 as well as‘s news article titled: “JPMorgan Chase details hiring plans for Raleigh, Chapel Hill branches – Triangle Business Journal” with publication date: March 13, 2019.

Jennison Associates Llc increased Netflix Inc (NASDAQ:NFLX) stake by 792,338 shares to 9.60M valued at $2.57B in 2018Q4. It also upped Verisk Analytics Inc (NASDAQ:VRSK) stake by 11,690 shares and now owns 304,241 shares. Q2 Hldgs Inc (NYSE:QTWO) was raised too.

Analysts await JPMorgan Chase & Co. (NYSE:JPM) to report earnings on April, 12. They expect $2.35 earnings per share, down 0.84% or $0.02 from last year’s $2.37 per share. JPM’s profit will be $7.70B for 11.34 P/E if the $2.35 EPS becomes a reality. After $1.98 actual earnings per share reported by JPMorgan Chase & Co. for the previous quarter, Wall Street now forecasts 18.69% EPS growth.

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. The company has market cap of $. It is developing Abicipar, a DARPin anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as is in Phase III clinical trials to treat diabetic macular edema diseases; and multi-VEGF/PDGF DARPin that is in preclinical studies for other ocular targets. It currently has negative earnings. The firm is also developing MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer.

JPMorgan Chase & Co. (NYSE:JPM) Institutional Positions Chart